880 Stroke Patients in Singapore to Undergo TCM Clinical Trial (Singapore)
This article was originally published in PharmAsia News
Singapore's National Medical Research Council has initiated the world's largest recorded clinical trial to test a stroke recovery treatment. Over the course of two years, researchers will evaluate the effectiveness of a traditional Chinese medicine known as NeuroAid on patients who have suffered a stroke in the past 48 hours. Neuroaid is already used around the world to support neurological performance. The study will include 1,100 subjects including 880 from Singapore itself. Additional patients will come from Thailand, the Philippines, and possibly Hong Kong. (Click here for more
You may also be interested in...
Pfizer’s abrocitinib and Biogen/Eisai’s aducanumab are among a host of new investigational products that are under review by the European Medicines Agency.
The UK's Celleron has attracted a "blue chip suite of investors" to an Irish-domiciled spin-off based on the potential of Roche-developed emactuzumab for TGCT, a debilitating orphan disease that causes joint damage and has limited clinical options.
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.